Autolus Therapeutics (NASDAQ:AUTL) announced its quarterly earnings results on Thursday. The company reported ($0.61) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.26, Fidelity Earnings reports. The company had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $2.00 million.
NASDAQ AUTL traded down $0.34 during trading on Friday, reaching $12.05. The company’s stock had a trading volume of 35,700 shares, compared to its average volume of 155,734. The firm has a market cap of $573.69 million, a price-to-earnings ratio of -8.49 and a beta of 0.67. The company has a debt-to-equity ratio of 0.09, a quick ratio of 13.12 and a current ratio of 13.12. The business’s fifty day moving average price is $12.51 and its 200-day moving average price is $15.66. Autolus Therapeutics has a twelve month low of $9.50 and a twelve month high of $53.24.
A number of equities research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $24.00 price target on shares of Autolus Therapeutics in a research report on Thursday, September 12th. Needham & Company LLC initiated coverage on shares of Autolus Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $26.00 price objective on the stock. William Blair restated a “buy” rating on shares of Autolus Therapeutics in a research note on Thursday. Finally, ValuEngine upgraded shares of Autolus Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $33.33.
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.
Featured Article: Are we seeing the beginning of a new bubble?
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.